The drug A-MIGDOBIS contains one active pharmaceutical ingredient (API):
Bismuth has weak antacid properties. Bismuth subsalicylate may exert its antidiarrhoeal action not only by stimulating absorption of fluid and electrolytes across the intestinal wall but also when hydrolysed to salicylic acid, by inhibiting synthesis of a prostaglandin responsible for intestinal inflammation and hypermotility.
This brand name is authorized in the following countries: Mexico
This drug has been assigned below unique identifiers within the countries it is being marketed: